T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods
AssigneeIcahn School of Medicine at Mount Sinai
InventorsJulie Magarian Blander, Miriam Torchinsky
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for modulation of TH17 responses. The invention provides compositions for the induction of TH17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing TH17 responses. In other embodiments, the invention provides compositions for the inhibition of TH17 responses containing one or more blocking agents. Methods and compositions for the modulation of TH17 responses and for the treatment of TH17-associated diseases and for cancer are also provided.
Claims40
(canceled)
An isolated TH17-inducing dendritic cell (DC) that secretes interleukin-6 (IL-6) and transforming growth factor beta (TGF-β), wherein the combined amount of IL-6 and TGF-β secreted by the TH17-inducing DC is effective for inducing a TH17 response when the TH17-inducing DC is administered to a subject.
-4. (canceled)
-7. (canceled)
-12. (canceled)
An immunogenic composition comprising a) a TH17-inducing DC that secretes IL-6 and TGF-β, (b) an immune antigen, and (c) a pharmaceutically acceptable carrier or diluent, wherein a combined amount of the IL-6 and the TGF-β secreted by the TH17-inducing DC and the immune antigen is effective for eliciting a TH17 response to the immune antigen in a subject which is administered the immunogenic composition.
(canceled)
(canceled)
-28. (canceled)
A composition comprising (a) a first blocking agent that inhibits immune recognition of an apoptotic cell-associated agent and (b) a second blocking agent that inhibits immune recognition of a TLR agonist.
-40. (canceled)
-46. (canceled)
(canceled)
Dependencies are inferred from the claim text.